v3.26.1
Industry Segment Information (Tables)
 6 Months Ended
Jul. 05, 2026
Segment Reporting [Abstract]  
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations
Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below:  
Three Months Ended
July 5, 2026June 29, 2025
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$358,699 $370,989 $729,688 $365,898 $354,386 $720,284 
Segment cost of revenue127,004 150,911 135,028 156,039 
Segment selling, general and administrative expenses93,804 84,652 86,986 84,127 
Segment research and development expenses26,357 22,560 28,415 24,798 
Segment operating income$111,534 $112,866 224,400 $115,469 $89,422 204,891 
Corporate expenses(13,391)(13,089)
Amortization of intangible assets(84,871)(85,289)
Purchase accounting adjustments(1,866)(2,178)
Acquisition and divestiture-related costs(105)(1,248)
Transformation costs736 — 
Significant litigation matters and settlements(79)(1,124)
Restructuring and other(35,508)(11,203)
Interest and other expense, net(25,785)(22,110)
Income from continuing operations before income taxes$63,531 $68,650 
Six Months Ended
July 5, 2026June 29, 2025
Life SciencesDiagnosticsTotalLife SciencesDiagnosticsTotal
(In thousands)
Segment revenue$720,544 $720,262 $1,440,806 $706,293 $678,753 $1,385,046 
Segment cost of revenue258,578 307,664 254,349 291,230 
Segment selling, general and administrative expenses188,472 174,844 174,081 174,017 
Segment research and development expenses57,981 48,766 56,683 50,069 
Segment operating income$215,513 $188,988 404,501 $221,180 $163,437 384,617 
Corporate expenses(25,638)(22,904)
Amortization of intangible assets(169,952)(167,989)
Purchase accounting adjustments(2,007)(2,001)
Acquisition and divestiture-related costs(387)(3,789)
Disposition of businesses and assets, net5,074 — 
Transformation costs(58)— 
Significant litigation matters and settlements(148)(11,710)
Significant environmental matters— 1,208 
Restructuring and other(46,183)(14,442)
Interest and other expense, net(51,679)(41,958)
Income from continuing operations before income taxes$113,523 $121,032 
Schedule of Depreciation [Table Text Block]
Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
Three Months EndedSix Months Ended
July 5,
2026		June 29,
2025		July 5,
2026		June 29,
2025
(In thousands)
Life Sciences$8,239 $8,547 $18,144 $15,732 
Diagnostics8,522 8,279 18,082 15,125 
Corporate407 665 917 1,356 
Total depreciation expense$17,168 $17,491 $37,143 $32,213